Tirzepatide-Induced Liver Injury: A Rare Medication Side Effect.

IF 0.6 Q4 GASTROENTEROLOGY & HEPATOLOGY

ACG Case Reports Journal Pub Date : 2025-04-10 eCollection Date: 2025-04-01 DOI:10.14309/crj.0000000000001661

Meagan Phox, John Thesing, W Ransom Kilgore, Joel Alderson

引用次数: 0

Abstract

Tirzepatide, an injectable agonist of glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors, is used to treat type 2 diabetes mellitus and obesity. To our knowledge, there have been few reported cases of drug-induced liver injury (DILI) secondary to tirzepatide use. We report the experience of a 76-year-old woman who developed acute hepatitis following 8 weeks of tirzepatide use and a sixteen-pound weight loss. She was found to have elevated liver enzymes, and liver biopsy confirmed DILI. Though the mechanism underlying this DILI remains unknown, physicians should be aware of this rare side effect.

查看原文本刊更多论文

替西肽引起的肝损伤：一种罕见的药物副作用。

替西肽是一种可注射的胰高血糖素样肽1和葡萄糖依赖性胰岛素性多肽受体激动剂，用于治疗2型糖尿病和肥胖症。据我们所知，使用替西肽引起药物性肝损伤（DILI）的报道很少。我们报告一位76岁妇女的经验，她在使用替西帕肽8周后出现急性肝炎，体重减轻了16磅。发现肝酶升高，肝活检证实DILI。虽然这种DILI的机制尚不清楚，但医生应该注意这种罕见的副作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACG Case Reports Journal GASTROENTEROLOGY & HEPATOLOGY-

自引率

14.30%

发文量

170

审稿时长

12 weeks

期刊介绍： ACG Case Reports Journal is a peer-reviewed, open-access publication that provides GI and hepatology fellows, private practice clinicians, and other healthcare providers an opportunity to share interesting case reports with their peers and with leaders in the field. ACG Case Reports Journal publishes case reports, images, videos and letters to the editor in all topics of gastroenterology and hepatology, including: Biliary Colon Endoscopy Esophagus Functional Bowel Disorders Inflammatory Bowel Disease Liver Nutrition and Obesity Pancreas Pathology Pediatric Small Bowel Stomach.